The phase 2 trial showed 17.1% average body weight reduction at 48 weeks with the 4mg dose
Red flag symptoms requiring urgent medical attention include: Signs of dehydration: excessive thirst, dark urine, dizziness, decreased urination, or confusion Severe abdominal pain, especially if localized to the right upper quadrant or accompanied by fever Blood in stool or black, tarry stools Persistent vomiting preventing adequate fluid intake Symptoms of pancreatitis: severe upper abdominal pain radiating to the back, nausea, and vomiting Rapid heart rate, weakness, or fainting Severe abdominal distension or inability to pass gas or stool (possible signs of intestinal obstruction) Seek emergency care (call 911 or go to the emergency department) for severe dehydration with confusion, fainting, or severe, unrelenting abdominal pain
But the clinical interpretation should remain cautious
GLP-1 injected subcutaneously simply took too long to reach receptors on target tissuesDPP-4 degraded the peptide within minutes
It's a cycle, really just a curve: you eat, GLP-1 increases, and over time it comes back down
The drug is an assist for people whose biology has been working against them
